Eli Lilly and (LLY) 10-K2015 FY Annual report

Filed: 19 Feb 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: Abasaglar, absorption, abundant, air, aircraft, alliance, appellate, assigned, asymptomatic, BioNTech, Breakthrough, Cadillac, canal, carrier, Classification, cluster, cMet, Codification, conclusion, CV, deem, deemed, dipotassium, disodium, dispersion, ear, Eleven, ENHANZE, epidermal, EPO, expert, extinguishment, facilitate, Fast, freight, gel, geography, glucagon, Halozyme, hand, Hanmi, happier, headache, Hexal, Hong, hundred, hypoglycemia, Imrestor, infection, inflammation, inquiry, instructed, inter, Interceptor, Internet, intranasal, investee, IPR, Iran, ITRSHRA, JPML, JPO, Kong, Kwikpen, legacy, lift, lifted, lifting, light, Limitada, Locemia, mania, mechanical, member, Missouri, mobile, nasal, Neptune, neurofibrillary, neutrophil, nondeductible, noninfringement, Notwithstanding, olaratumab, Onsior, Osurnia, overturned, passage, penetration, Pennsylvania, pervasive, Portrazza, powder, preserved, presumption, proceed, professional, proof, proportion, rationalization, recovery, redemption, reliever, repay, residual, sarcoma, shipment, slight, slightly, soft, space, spot, subcutaneously, suspended, Synjardy, Syria, Taiwan, tau, thousand, Threat, tissue, tracer, Track, unidentified, USPTO, withdrew

Removed: admitting, advance, allegedly, amounted, anemia, Barr, bioscience, ChemGen, cholesteryl, compensatory, consented, consultant, debated, decreasing, Delaware, denying, dilutive, dispute, dosage, dulaglutide, egg, endothelial, ester, exercise, glucose, Hrvatska, importation, impose, initiative, intrinsic, investigation, letter, liprotamase, meat, nominal, notified, Oberhelman, parent, pen, Pharma, pharmacological, Pliva, Poland, Polish, postretirement, prejudice, prepayment, punitive, ramucirumab, renal, resubmission, secondary, sodium, stop, survival, tabalumab, taxation, topic, transition, vascular, vested, withdrawal

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

LLY similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 12. Statement Re: Computation of Ratio of Earnings to Fixed Charges

ELI LILLY AND COMPANY AND SUBSIDIARIES



		Years Ended December 31,
		2015			2014			2013			2012			2011
	(Dollars in millions)
Consolidated pretax income		$	2,790.0		$	3,000.3		$	5,889.3		$	5,408.2		$	5,349.5
Interest⁽¹⁾		216.0			187.1			184.2			198.8			211.7
Less interest capitalized during the period		(54.8		)	(38.3		)	(24.1		)	(21.0		)	(25.7		)
Earnings		$	2,951.2		$	3,149.1		$	6,049.4		$	5,586.0		$	5,535.5
Fixed charges		$	216.0		$	187.1		$	184.2		$	198.8		$	211.7
Ratio of earnings to fixed charges		13.7			16.8			32.8			28.1			26.1

⁽¹⁾Interest is based upon interest expense reported as such in the consolidated statements of operations and does not include any interest related to unrecognized tax benefits, which is included in income tax expense.